One of the notable advances has been the introduction of sodium-glucose co-transporter-2 (SGLT2) inhibitors, initially developed for type 2 diabetes mellitus (T2DM), but now recognized for their efficacy in managing HF, particularly in patients with HFrEF [4,5]. Here, SLC5A2 is linked to type 2 diabetes mellitus.